See more : Naito & Co., Ltd. (7624.T) Income Statement Analysis – Financial Results
Complete financial analysis of Rigel Pharmaceuticals, Inc. (RIGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rigel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- JPMorgan Global Growth & Income plc (JGGI.L) Income Statement Analysis – Financial Results
- Hess Corporation (HES) Income Statement Analysis – Financial Results
- Budweiser Brewing Company APAC Limited (1876.HK) Income Statement Analysis – Financial Results
- Döhler S.A. (DOHL4.SA) Income Statement Analysis – Financial Results
- Ai-Media Technologies Limited (AIM.AX) Income Statement Analysis – Financial Results
Rigel Pharmaceuticals, Inc. (RIGL)
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.88M | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M | 4.48M | 20.38M | 28.90M | 8.25M | 7.15M | 2.25M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 13.22M | 8.98M |
| Cost of Revenue | 7.11M | 1.75M | 1.08M | 895.00K | 906.00K | 287.00K | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.56M | -1.91M |
| Gross Profit | 109.77M | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M | -41.79M | -43.06M | -33.93M | -59.45M | -68.18M | -76.53M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 20.78M | 10.89M |
| Gross Profit Ratio | 93.92% | 98.55% | 99.27% | 99.18% | 98.47% | 99.36% | -931.87% | -211.27% | -117.43% | -720.56% | -953.54% | -3,401.24% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 157.17% | 121.22% |
| Research & Development | 24.52M | 60.27M | 65.24M | 60.10M | 52.89M | 46.90M | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 69.35M | 64.39M | 90.74M | 109.67M | 70.36M | 56.97M | 52.04M | 48.52M | 43.36M | 43.35M | 32.31M | 32.03M | 17.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 105.74M | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 3.95M |
| Other Expenses | 0.00 | 1.32M | 3.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.56M | 1.91M |
| Operating Expenses | 130.26M | 172.72M | 157.13M | 136.70M | 127.47M | 116.91M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 46.28M | 22.97M |
| Cost & Expenses | 137.37M | 174.47M | 158.21M | 137.59M | 128.38M | 117.19M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 38.72M | 21.06M |
| Interest Income | 2.27M | 684.00K | 47.00K | 582.00K | 2.53M | 2.20M | 892.00K | 437.00K | 222.00K | 243.00K | 442.00K | 537.00K | 420.00K | 303.00K | 600.00K | 4.44M | 5.48M | 5.70M | 2.94M | 966.00K | 374.00K | 856.00K | 1.96M | 1.08M | 0.00 |
| Interest Expense | 6.87M | 3.71M | 4.86M | 1.35M | 335.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 17.00K | 25.00K | 91.00K | 203.00K | 160.00K | 221.00K | 290.00K | 276.00K | 324.00K | 575.00K | 870.00K | 802.00K | 933.00K | 0.00 |
| Depreciation & Amortization | 1.24M | 998.00K | 1.16M | 706.00K | 683.00K | 594.00K | 465.00K | 941.00K | 1.44M | 2.36M | 2.59M | 2.43M | 1.96M | 1.32M | 1.40M | 1.43M | 1.34M | 1.42M | 1.18M | 2.37M | 3.18M | 5.82M | 6.76M | 7.56M | 1.91M |
| EBITDA | -16.98M | -53.87M | -11.29M | -27.69M | -65.88M | -69.89M | -77.53M | -63.03M | -50.30M | -88.89M | -85.20M | -96.94M | -83.99M | 39.30M | -110.03M | -130.85M | -79.53M | -43.05M | -47.92M | -54.49M | -37.65M | -31.19M | -18.20M | -17.95M | -10.17M |
| EBITDA Ratio | -14.53% | -44.53% | -5.98% | -26.14% | -112.26% | -163.30% | -1,791.88% | -285.97% | -179.27% | -1,107.24% | -1,185.40% | -4,416.76% | -1,768.27% | 29.55% | -14,519.07% | 0.00% | -620.50% | -124.37% | -282.84% | -1,150.73% | -339.04% | -197.57% | -118.93% | -135.78% | -113.25% |
| Operating Income | -20.49M | -54.23M | -8.98M | -28.97M | -69.09M | -72.68M | -79.62M | -69.74M | -51.74M | -91.25M | -89.47M | -99.38M | -86.37M | 35.32M | -112.04M | -136.71M | -79.53M | -43.05M | -47.92M | -56.87M | -40.83M | -37.02M | -24.96M | -25.51M | -12.08M |
| Operating Income Ratio | -17.53% | -45.10% | -6.01% | -26.67% | -116.53% | -163.30% | -1,775.56% | -342.15% | -179.07% | -1,106.05% | -1,251.31% | -4,416.76% | -1,818.27% | 28.25% | -14,938.27% | 0.00% | -631.17% | -128.60% | -289.98% | -1,201.50% | -369.31% | -234.46% | -163.11% | -192.96% | -134.46% |
| Total Other Income/Expenses | -4.60M | -3.02M | -4.81M | -771.00K | 2.20M | 2.20M | 1.62M | 525.00K | 279.00K | 341.00K | 442.00K | 537.00K | 395.00K | 2.57M | 397.00K | 4.28M | 5.26M | 5.41M | 2.67M | 612.00K | -370.00K | -14.00K | 1.16M | 145.00K | 0.00 |
| Income Before Tax | -25.09M | -58.57M | -17.31M | -29.74M | -66.89M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.64M | -132.44M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | 0.00 |
| Income Before Tax Ratio | -21.47% | -48.71% | -11.60% | -27.38% | -112.83% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,885.33% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | 0.00% |
| Income Tax Expense | 0.00 | 3.02M | 605.00K | 647.00K | -348.00K | 2.20M | -2.09M | 4.30M | -1.72M | -2.70M | 0.00 | -2.43M | 420.00K | 91.00K | -93.00K | -89.00K | 0.00 | 0.00 | 0.00 | -612.00K | 370.00K | 0.00 | 0.00 | 0.00 | 286.00K |
| Net Income | -25.09M | -61.60M | -17.91M | -30.39M | -66.55M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.55M | -132.35M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | -12.37M |
| Net Income Ratio | -21.47% | -51.23% | -12.00% | -27.98% | -112.24% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,872.93% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | -137.64% |
| EPS | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.73 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
| EPS Diluted | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.72 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
| Weighted Avg Shares Out | 17.40M | 17.24M | 17.05M | 16.88M | 16.72M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.88M | 63.33M | 52.06M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
| Weighted Avg Shares Out (Dil) | 17.40M | 17.24M | 17.05M | 16.88M | 16.74M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.97M | 63.33M | 52.57M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
5 Relative Price Strength Options Available for Investors
Rigel to Present at the Jefferies London Healthcare Conference
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
Source: https://incomestatements.info
Category: Stock Reports